Fear of competitors leveraging AI successfully, coupled with significant investments required in talent, infrastructure and ...

Learn how advanced context design and Claude Code elevate AI performance, turning tools into extraordinary problem-solvers.

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its shares ...